{
    "clinical_study": {
        "@rank": "144731", 
        "arm_group": [
            {
                "arm_group_label": "Pinocembrin for Injection", 
                "arm_group_type": "Experimental", 
                "description": "40mg /60mg in 100ml of a solution of 0.9 percent saline,iv.drip bid,14day"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "60mg in 100ml of a solution of 0.9 percent saline,iv.drip bid,14day"
            }
        ], 
        "brief_summary": {
            "textblock": "This research is a Randomized, double-blind, placebo-controlled, multicenter clinical study.\n      Chinese subjects with Ischemic Stroke."
        }, 
        "brief_title": "Phase \u2161Study of Pinocembrin Injection to Treat Ischemic Stroke", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Ischemic Stroke", 
        "condition_browse": {
            "mesh_term": [
                "Ischemia", 
                "Stroke", 
                "Cerebral Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "Subjects will randomly enter into one of two groups,the period of treatment is 14\n      days,follow-up to the 90th days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must be 35-75years old(hospital patients) ,both male and female; Patients\n             had a clinical diagnosis of acute stroke that had commenced within the six hours\n             before entry into the study; Patients had a score of 6-20 on the National Institutes\n             of Health Stroke Scale and the score \u22652 of item 5 and/or 6; For the first time or\n             always without obvious sequelae of stroke disease(mRS\u22641\uff09\n\n        Exclusion Criteria:\n\n          -  The disease such as Acute intracerebral hemorrhage,tumor and encephalitis ;cause\n             which cause  similar symptoms; TIA; Pregnancy and breast-feeding women and male\n             subjects with fertility program"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "216", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02059785", 
            "org_study_id": "CSPC-HA1301"
        }, 
        "intervention": {
            "arm_group_label": "Pinocembrin for Injection", 
            "intervention_name": "Pinocembrin for Injection", 
            "intervention_type": "Drug", 
            "other_name": "DL0108"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pinocembrin for Injection", 
            "Placebo", 
            "mRS"
        ], 
        "lastchanged_date": "February 7, 2014", 
        "location": {
            "contact": {
                "last_name": "Wang Yong Jun, Ph.D", 
                "phone": "86-01-67096611"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100050"
                }, 
                "name": "Beijing Tiantan Hospital affilliated to Capital Medical University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase \u2161Study of Pinocembrin Injection to Treat Ischemic Stroke---Randomized, Double-blind, Placebo-controlled, Multicenter Study", 
        "overall_contact": {
            "last_name": "Yan Ji Ling, Master", 
            "phone": "86-311-67808812"
        }, 
        "overall_official": {
            "affiliation": "Beijing Tiantan Hospital affilliated to Capital Medical University", 
            "last_name": "Wang Yong Jun, Ph.D", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To determination the proportion of subjects that 0-1 score of mRS after treatment 90 days", 
            "safety_issue": "No", 
            "time_frame": "90 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02059785"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "To compare treatment arms in terms of change from baseline to endpoint in NIHSS score.", 
            "safety_issue": "No", 
            "time_frame": "90 days"
        }, 
        "source": "CSPC ZhongQi Pharmaceutical Technology Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CSPC ZhongQi Pharmaceutical Technology Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}